|Videos|July 20, 2022

Urology Times 50 Innovations Series: LHRH analogues in prostate cancer

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

Episodes in this series

As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME